Compare Novartis AG (NVS) vs Health Care Select Sector SPDR Fund (XLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Health Care Select Sector SPDR Fund — how do they compare? Novartis AG trades at $139.3 (market cap $262.64B), while Health Care Select Sector SPDR Fund trades at $166.98. The key difference: Novartis AG pays a 3.44% dividend while Health Care Select Sector SPDR Fund pays none, and Health Care Select Sector SPDR Fund is trading nearer its 52-week high, Novartis AG nearer its low. Which is the better fit depends on your goals.
| NVS | XLV | |
|---|---|---|
Market Cap | $262.64B | — |
Sector | Health | — |
52-Week High | $168.62 | $175.68 |
52-Week Low | $121.80 | $134.13 |
Enterprise Value | $303.97B | — |
Dividend Yield | 3.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.
While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.
XLV trades at $167.16, down 2.5% amid testing key support levels, with technical indicators showing mixed signals between bullish moving averages and bearish oscillators. The healthcare ETF maintains defensive appeal with upcoming dividend payments and steady institutional interest, though recent options activity shows increased put volume. Healthcare sector momentum remains supported by strong earnings and defensive positioning in volatile markets.
Outlook remains cautiously optimistic given healthcare's defensive characteristics and potential Fed rate hike benefits, though near-term technical weakness and sector-specific headwinds like drug trial failures present risks. The ETF's low expense ratio and diversification across 60 healthcare stocks provide stability for long-term investors seeking sector exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Health Care Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies from the following industries: pharmaceuticals; health care equipment & supplies; health care providers & services; biotechnology; life sciences tools & services; and health care technology. The fund is non-diversified.
Read more on XLV →
